Aclaris Therapeutics (ACRS) Total Debt (2017 - 2022)

Aclaris Therapeutics' Total Debt history runs 6 years deep, the most recent figure standing at $2.7 million for Q3 2022.

• On a quarterly basis, Total Debt fell 12.2% year-over-year to $2.7 million in Q3 2022; TTM through Sep 2022 was $2.7 million, a 12.2% decrease from a year earlier, with the FY2021 full-year figure at $2.6 million, down 75.12% from the prior year.
• Total Debt steadied at $2.7 million in Q3 2022 per ACRS's latest filing, from $2.7 million in the prior quarter.
• Across five years, Total Debt topped out at $29.9 million in Q3 2019 and bottomed at $2.6 million in Q4 2021.
• The 5-year median for Total Debt is $10.6 million (2020), against an average of $13.4 million.
• Across the five-year window, Total Debt jumped 4970.17% in 2018 and plunged 80.44% in 2022, its largest moves.
• Year by year, Total Debt stood at $29.9 million in 2018, then increased by 0.05% to $29.9 million in 2019, then tumbled by 64.41% to $10.7 million in 2020, then slumped by 75.12% to $2.6 million in 2021, then grew by 1.89% to $2.7 million in 2022.
• Per Business Quant, the three latest ACRS Total Debt figures stand at $2.7 million (Q3 2022), $2.7 million (Q2 2022), and $2.7 million (Q1 2022).